|
|
Vaccine Detail
|
Mutant VEGF165b-MUC1 Fusion Protein Vaccine |
| Vaccine Information |
- Vaccine Name: Mutant VEGF165b-MUC1 Fusion Protein Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant subunit fusion protein vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Liang et al., 2024)
-
Adjuvant:
CFA/IFA (Liang et al., 2024)
- Immunization Route: subcutaneous injection
- Description: A recombinant fusion protein vaccine consisting of plasmin-resistant VEGF165b mutant (mVEGF165b, containing A111P substitution) genetically fused via an AAY linker to a 24-amino acid MUC1 T-cell epitope peptide (STAPPAHGVTSPDTRPAPGSTAPP) derived from the Mucin1 VNTR region. The mVEGF165b component serves dual functions as both a protein carrier to enhance peptide stability and immunogenicity, and as an antigen to elicit anti-VEGF antibodies. Immunization induces high-titer anti-VEGF antibodies (1:1,400,000 titer) that reduce regulatory T cell (Treg) proportions, promote tumor blood vessel maturation, and enhance CD8+ T-cell tumor infiltration. The vaccine stimulates MUC1-specific cytotoxic T-lymphocyte responses, with CD8+ IFN-γ+ T cells increased 10-fold compared to control and 2-fold compared to individual components. In preventive BALB/c mouse models using Mucin1-expressing EMT-6 breast cancer cells, immunization extended median survival to 25 days versus 15 days in controls and demonstrated comparable efficacy to combined administration of separate mVEGF165b and MUC1 components. The MUC1 peptide targets aberrantly glycosylated Mucin1 overexpressed in more than 90% of breast and other cancers (Liang et al., 2024).
|
| Host Response |
|
|
| References |
Liang et al., 2024: Liang C, Geng L, Dong Y, Zhang H. VEGF165b mutant can be used as a protein carrier to form a chimeric tumor vaccine with Mucin1 peptide to elicit an anti-tumor response. Molecular immunology. 2024; 175; 31-39. [PubMed: 39298996].
|
|
